Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
February 7, 2005
- Sosei, Abgenix Jointly Identify Lead Antibodies
February 7, 2005
- Mochida to Beef Up Split-off Houses
February 7, 2005
- Thalidomide Given Orphan Status
February 7, 2005
- Ryukinkyo's Model Contracts Need Revisions: EAD Director
February 7, 2005
- Insurance Rate to Differ in Each Pref.: Proposal
February 7, 2005
- REGULATORY NEWS IN BRIEF
February 7, 2005
- Aiming at an Over 4% Market Share by 2007: Mr Baba of Novartis
February 7, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 7, 2005
- BULLETIN
February 7, 2005
- AnGes MG to Jointly Research on Gene Therapy with Univ. of Tokyo Hospital
February 7, 2005
- Nakakita to Consolidate Its Position as Regional Wholesaler
February 7, 2005
- MediBIC to Codevelop Anticancer Agent with Threshold Pharmaceuticals
February 7, 2005
- BUSINESS NEWS IN BRIEF
February 7, 2005
- Strong Demand for Microdose Clinical Studies
February 7, 2005
- BUSINESS SEMINAR
February 7, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 7, 2005
- WEBSITE NEWS
February 7, 2005
- Press Seminar
February 7, 2005
- BULLETIN
February 7, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…